LAVAL, Quebec , Aug. 10, 2022 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the particular company’s July 28, 2022 , press release, the U. S. District Court of Delaware has issued a decision in the matter associated with Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceutical drugs, Inc. finding certain XIFAXAN® (rifaximin) 550 mg HE patents valid and infringed and certain XIFAXAN composition and IBS-D patents invalid.   As previously stated, the Company will appeal this decision in order to the Oughout. S. Courtroom of Appeal for the particular Federal Signal and it expects an appeal decision to issue within 12 in order to 18 months.

To date, Norwich has not received tentative or final approval of its ANDA from the FDA.   Unless and until FDA approves a revised Norwich ANDA that omits the XIFAXAN HE indication, and any injunction issued by the Court is modified, Norwich is not permitted to launch a generic equivalent of XIFAXIN.

About XIFAXAN

XIFAXAN®  (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the particular treatment associated with irritable bowel syndrome with diarrhea (IBS-D) in adults.

About Salix

Salix Pharmaceuticals will be one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix offers licensed, developed and marketed innovative products to improve patients’ lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to You. S. healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey . For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.

About Bausch Health

Bausch Health Businesses Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is in order to improve people’s lives along with our medical care products. We develop, manufacture and market a range of items primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our approximately 90% ownership of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter plus LinkedIn .

Forward-looking Statements This news release may contain forward-looking statements about the future performance associated with Bausch Wellness, which may generally be identified by the use of the words “anticipates, ” “hopes, ” “expects, ” “intends, ” “plans, ” “should, ” “could, ” “would, ” “may, ” “believes, ” “subject to” and variations or even similar expressions, including claims about the particular Company’s intentions to file an appeal with respect to, and take actions in order to vigorously defend, its intellectual property. These statements are based upon the current expectations and beliefs of management and are usually subject to particular risks plus uncertainties that will could cause actual results to differ materially from those described in the forward-looking statements. In particular, Bausch Health can offer no assurance as to the particular timing of any authorization by the FOOD AND DRUG ADMINISTRATION of any kind of ANDA or amended KAMU and as to the outcome of any attractiveness. Actual results are subject in order to other risks and uncertainties that relate more broadly to Bausch Health’s overall business, including those more fully described in Bausch Health’s most recent annual report upon Form 10-K and detailed from time to period in Bausch Health’s other filings along with the  U. S.   Securities and Exchange Commission and the Canadian securities administrators, which factors are incorporated herein by reference.

Investor Contact:

Media Contacts:



Christina Cheng

Kevin Wiggins                                     

[email protected]

[email protected]

(514) 856-3855

(848) 541-3785   

(877) 281-6642 (toll free)

SOURCE Bausch Wellness Companies Inc.

Leave a Reply

Your email address will not be published.